George Ansstas
Overview
Explore the profile of George Ansstas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1027
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun L, Krigman H, Rohatgi A, Ansstas G, Hughes A
Clin Chem
. 2025 Mar;
71(3):351-355.
PMID: 40037409
No abstract available.
2.
Nassief G, Anaeme A, Moussa K, Mansour A, Ansstas G
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337333
Malignant melanoma outcomes have drastically changed in recent years due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients still experience intolerable side effects, therapy resistance, and disease...
3.
Hughes B, Guminski A, Bowyer S, Migden M, Schmults C, Khushalani N, et al.
J Am Acad Dermatol
. 2024 Sep;
92(1):68-77.
PMID: 39245360
Background: In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC). Objectives: To report...
4.
Phillipps J, Nassief G, Morecroft R, Adeyelu T, Elliott A, Abdulla F, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):187.
PMID: 39232122
Modern advancements in targeted therapy and immunotherapy have significantly improved survival outcomes for advanced melanoma; however, there remains a need for novel approaches to overcome disease progression and treatment resistance....
5.
Nassief G, Anaeme A, Moussa K, Chen D, Ansstas G
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065766
Skin cancer prognosis has greatly improved recently due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients with advanced skin cancer still experience immunotherapy resistance and disease progression...
6.
Morecroft R, Phillipps J, Zhou A, Butt O, Khaddour K, Johanns T, et al.
Front Oncol
. 2024 May;
14:1385094.
PMID: 38779101
Immunotherapy is the first-line option for treating advanced cutaneous squamous cell carcinoma (cSCC). However, up to half of patients experience no benefit and treatment resistance, warranting newer therapeutic approaches. Combinatory...
7.
Nassief G, Butt O, Zhou A, Ansstas G
JAAD Case Rep
. 2024 May;
48:59-61.
PMID: 38778889
No abstract available.
8.
Huang J, Campian J, DeWees T, Skrott Z, Mistrik M, Johanns T, et al.
Int J Radiat Oncol Biol Phys
. 2024 May;
120(3):738-749.
PMID: 38768767
Purpose: This phase 1/2 study aimed to evaluate the safety and preliminary efficacy of combining disulfiram and copper (DSF/Cu) with radiation therapy (RT) and temozolomide (TMZ) in patients with newly...
9.
Akinjiyan F, Nassief G, Phillipps J, Adeyelu T, Elliott A, Abdulla F, et al.
Sci Rep
. 2024 Feb;
14(1):3444.
PMID: 38341515
ARID genes encode subunits of SWI/SNF chromatin remodeling complexes and are frequently mutated in human cancers. We investigated the correlation between ARID mutations, molecular features, and clinical outcomes in melanoma...
10.
Weber J, Carlino M, Khattak A, Meniawy T, Ansstas G, Taylor M, et al.
Lancet
. 2024 Jan;
403(10427):632-644.
PMID: 38246194
Background: Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy,...